Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug
AssigneeMerck & Co., Inc.
InventorsJoanne Waldstreicher, Briggs W. Morrison
Life of this patent
Estimating the term…
Abstract
A COX-2 selective inhibiting drug is disclosed as useful in treating or preventing prostate cancer. The compound is used alone or in combination with other drugs.
Claims10
A method of treating or preventing prostate cancer in a male mammalian patient in need thereof, comprising administering to said patient a COX-2 selective inhibiting compound in an amount that is effective to treat or prevent prostate cancer, wherein the COX-2 selective inhibiting compound is rofecoxib.
A method of treating or preventing prostate cancer in a male mammalian patient comprising administering to the patient rofecoxib in combination with radiation therapy.
Dependencies are inferred from the claim text.